Business · 09/10/2026Updated: 10/15/2026 · 1 min read
Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications; Correction
Summary
The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register on June 3, 2026, regarding the withdrawal of approval of 16 abbreviated new drug applications (ANDAs) filed by Elite Laboratories, Inc. and other companies.
Original source language: Federal Register — Health and Human ServicesOpen original release →